Enriquez-Geppert, S.; Bevers, L.; Rosander, A.; Fodran, P.; Polito, V.
Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development. Biomolecules 2026, 16, 983.
https://doi.org/10.3390/biom16070983
AMA Style
Enriquez-Geppert S, Bevers L, Rosander A, Fodran P, Polito V.
Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development. Biomolecules. 2026; 16(7):983.
https://doi.org/10.3390/biom16070983
Chicago/Turabian Style
Enriquez-Geppert, Stefanie, Lisa Bevers, Arvid Rosander, Peter Fodran, and Vince Polito.
2026. "Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development" Biomolecules 16, no. 7: 983.
https://doi.org/10.3390/biom16070983
APA Style
Enriquez-Geppert, S., Bevers, L., Rosander, A., Fodran, P., & Polito, V.
(2026). Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development. Biomolecules, 16(7), 983.
https://doi.org/10.3390/biom16070983
_Kwok.png)
